Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study)

Pauciullo, Paolo; Borgnino, C.; Paoletti, Rodolfo; Mariani, Mario; Mancini, Mario

doi:10.1016/s0021-9150(00)00379-8

Cited by 63 publications

(30 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The most potent triglyceridelowering agents available are fibrates, with the combination of a fibrate and statin providing complementary lipid-lowering effects. In numerous studies, this combination has been shown to control elevations in both LDL cholesterol and triglyceride levels [19][20][21][22][23]. However, concomitant use of a fibrate and a statin has been associated with an increased risk of myopathy.…”

Section: Discussionmentioning

confidence: 99%

Combination Lipid Therapy on Lipid Profiles in Patients with Impaired Glucose Tolerance

Kawano¹,

Nagayoshi²,

Ogawa³

et al. 2013

IJCM

View full text Add to dashboard Cite

Objective: This study compared the effects of combination statin and fibrate therapy with either statin or fibrate monotherapy on lipid profiles in patients with impaired glucose tolerance (IGT) and a high risk for cardiovascular disease. Methods & Patients:Forty-five patients with IGT and dyslipidemia (men 25, women 20, mean age 61.7 ± 2.4 yrs) were assigned randomly to the 3 treatment groups for a 6-month period. Results: After 6 months of treatment, low density lipoprotein levels decreased in every group, especially the statin and statin + fibrate groups. Triglyceride levels also decreased in all three groups, especially the fibrate and statin + fibrate groups. High density lipoprotein cholesterol and fasting blood glucose levels did not change in any group. The levels of remnant like cholesterol particles decreased in the fibrate and statin + fibrate groups. There was no change during the study in the levels of creatine phosphokinase, lactate dehydrogenase, or creatinine. Conclusion: Combination statin and fibrate therapy results in greater improvement in lipid profiles than monotherapy with either drug. No marked adverse effects were observed with combination therapy during the study.

show abstract

Section: Discussionmentioning

confidence: 99%

Combination Lipid Therapy on Lipid Profiles in Patients with Impaired Glucose Tolerance

Kawano¹,

Nagayoshi²,

Ogawa³

et al. 2013

IJCM

View full text Add to dashboard Cite

show abstract

“…Numerous studies have demonstrated long-term efficacy and safety with combination lipid-lowering therapy (16)(17)(18)(19)(20)(21). The HDL-Atherosclerosis Treatment Study (HATS) showed that a striking reduction in outcomes can be achieved by combination treatment (20).…”

Section: Discussionmentioning

confidence: 99%

Reaching Target Lipid Levels in Patients at High Risk of Cardiovascular Event: The Experience of a Canadian Tertiary Care Lipid Clinic

Klinke¹,

Málek²,

Gao³

et al. 2007

Cent Eur J Public Health

View full text Add to dashboard Cite

SummaryObjectives: To determine the proportion of high risk patients followed at a tertiary care lipid clinic who met recommended lipid targets and to identify predictors of reaching goal lipid levels.Research design and methods: A retrospective cohort study of 502 high risk patients followed between 1983 and 2003. Clinical and demographic data and fasting lipid profiles were extracted from each patient's first two clinic visits as well as the most recent visit.Results: All patients in this study were at high risk of cardiovascular events due to dyslipidemia. At "Visit 1", only 55 (11.0%) of patients were at target TC/HDL-C < 4.0, and 97 (19.3%) of patients met target LDL-C < 2.5 mmol/l. At "Visit 3", 229 (45.8%) patients reached TC/HDL-C target, and 216 (43.2%) patients were at LDL-C target. The mean change in lipid values between Visit 1 and Visit 3 was significant (p = 0.0002) for LDL-C and (p < 0.0001) for TC/HDL-C. The use of statins, niacin, or salmon oil were all significantly associated with reaching TC/HDL-C target and LDL-C target, as well male gender, diabetes mellitus and peripheral vascular disease were also associated with reaching LDL-C target. Increasing age and lower body mass index were associated with reaching goal TC/HDL-C.Conclusions: The mean absolute changes in lipid values were significant and median lipid levels approached target levels in patients followed at specialized clinic, however the majority of high risk patients are not meeting goal lipid levels.

show abstract

“…The Fluvastatin Alone and in Combination Treatment (FACT) study was a multicenter, prospective, double-blind study of 333 patients with CAD and combined dyslipidemia. The combination of fluvastatin 40 mg plus bezafibrate 400 mg was very effective for all lipid parameters, decreasing LDL cholesterol by 24% and triglycerides by 38% and increasing HDL cholesterol by 22% 51) . Action to Control Cardiovascular Risk in Diabetes (ACCORD) was designed to address the effect of add-on therapy of fenofibrate to simvastatin in type 2 diabetes patients; however, the combination of fenofibrate and simvastatin did not reduce the rate of fatal cardiovascular events, nonfatal myocardial infarction, or nonfatal stroke, as compared with simvastatin alone 52) .…”

Section: Statin-fibrate Combination Therapymentioning

confidence: 93%

Management of Type IIb Dyslipidemia

Arai

Ishibashi

Bujo

et al. 2012

JAT

View full text Add to dashboard Cite

Although the Japan Atherosclerosis Society guideline for the diagnosis and prevention of atherosclerosis cardiovascular diseases for the Japanese population provides targets for low-density lipoprotein (LDL) cholesterol, triglycerides, and high-density lipoprotein (HDL) cholesterol to prevent cardiovascular disease in patients with dyslipidemia, there is no guideline specifically targeting the treatment of type b dyslipidemia, which is one of the most common types of dyslipidemia, along with type a and type dyslipidemia. Type b dyslipidemia is important because it sometimes accompanies atherogenic lipid profiles, such as small, dense LDL, remnants, low HDL cholesterolemia. It is also associated with type 2 diabetes mellitus, metabolic syndrome, and chronic kidney disease (CKD), and most patients with familial combined hyperlipidemia (FCHL) show this phenotype; therefore, it is assumed that patients with type b dyslipidemia have a high risk for cardiovascular disease. Thus, the management of type b dyslipidemia is very important for the prevention of cardiovascular disease, so we have attempted to provide a guideline for the management of type b dyslipidemia.

show abstract

Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study)

Cited by 63 publications

References 33 publications

Combination Lipid Therapy on Lipid Profiles in Patients with Impaired Glucose Tolerance

Combination Lipid Therapy on Lipid Profiles in Patients with Impaired Glucose Tolerance

Reaching Target Lipid Levels in Patients at High Risk of Cardiovascular Event: The Experience of a Canadian Tertiary Care Lipid Clinic

Management of Type IIb Dyslipidemia

Contact Info

Product

Resources

About